As the year comes to a close, we revisit some of this year’s top content on prostate cancer.
There’s been an abundance of news surrounding prostate cancer over the past year. In light of all that has been discovered, Urology Times® is counting down the top pieces of content surrounding prostate cancer in 2022.
Fred Saad, MD, FRCS, discusses the background and findings of the study, “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Watch now.
Ian D. Davis, MBBS, PhD, FRACP, FAChPM, interpreted the clinical significance of findings from the ENZAMET study for the management of patients with metastatic hormone-sensitive prostate cancer, which were presented at the 2022 ASCO Annual Meeting. Watch now.
Rahul Aggarwal, MD, discussed data from the phase 3 PRESTO trial, which he presented at the 2022 ESMO Congress. Watch now.
Intensification of androgen-deprivation therapy with the addition of the androgen receptor inhibitor apalutamide (Erleada) showed potential as a treatment for patients with high-risk biochemically relapsed prostate cancer, according to findings from the phase 3 PRESTO trial presented at the 2022 ESMO Congress. Read more.
The FDA approved the targeted radioligand therapy 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. Read more.
Experts at the University of Cambridge, United Kingdom, warned that public health messaging labeling urinary symptoms as a key indicator of prostate cancer may be detrimental to efforts to improve health outcomes for the disease. Read more.
A study published in BMC Urology stressed the importance of considering benign prostatic hyperplasia symptoms at baseline to ensure optimal treatment selection for some patients with early early-stage prostate cancer. Read more.
At the 15th Annual meeting of the Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies (NY GU 2022),Scott T. Tagawa, MD, MS, FACP, discussed how the increased prevalence of radiopharmaceuticals has provided the opportunity for patients with prostate cancer to preserve their quality of life. Read more.
The National Comprehensive Cancer Network and the Society of Nuclear Medicine and Molecular Imaging guidelines now include the use of piflufolastat F 18 (Pylarify), along with all approved PSMA-PET imaging agents, for the selection of prostate cancer patients to receive PSMA-targeted radioligand therapy. Read more.
Professors Craig Crews and Daniel Petrylak at the Yale School of Medicine collaborated to develop a new drug that treats cancer by tagging specific problem cells for destruction. Proteolysis-targeting chimaera, or PROTACs, showed promise in clinical trials. Read more.